Jennifer C Spencer1, Bryce B Reeve2,3, Melissa A Troester4, Stephanie B Wheeler1,5. 1. Department of Health Policy and Management, University of North Carolina at Chapel Hill. 2. Department of Population Health Sciences, Duke University School of Medicine. 3. Duke Cancer Institute, Duke University School of Medicine. 4. Department of Epidemiology, University of North Carolina at Chapel Hill. 5. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.
Abstract
BACKGROUND: For women with hormone receptor positive breast cancer, long-term endocrine therapy (ET) can greatly reduce the risk of recurrence, yet adherence is low- particularly among traditionally underserved populations. METHODS: The Carolina Breast Cancer Study oversampled Black and young women (<50 years of age). Participants answered an ET-specific medication adherence questionnaire assessing reasons for non-adherence. We used principal factor analysis to identify latent factors describing ET non-adherence. We then performed multivariable regression to determine clinical and demographic characteristics associated with each ET non-adherence factor. RESULTS: 1,231 women were included in analysis, 59% reported at least one barrier to ET adherence. We identified three latent factors which we defined as: habit - challenges developing medication-taking behavior; tradeoffs - high perceived side effect burden and medication safety concerns; and resource barriers - challenges related to cost or accessibility. Older age (50+) was associated with less reporting of habit (Adjusted Risk Ratio (aRR) 0.54[95% CI: 0.43-0.69] and resource barriers (aRR 0.66[0.43-0.997]), but was not associated with tradeoff barriers. Medicaid-insured women were more likely than privately-insured to report tradeoff (aRR:1.53 [1.10-2.13]) or resource barriers (aRR:4.43[2.49-6.57]). Black race was associated with increased reporting of all factors (habit: aRR 1.29[1.09-1.53]; tradeoffs: 1.32[1.09-1.60], resources: 1.65[1.18-2.30]). CONCLUSION: Barriers to ET adherence were described by three distinct factors, and strongly associated with sociodemographic characteristics. Barriers to ET adherence appear inadequately addressed for younger, Black, and publicly-insured breast cancer survivors. These findings underscore the importance of developing multi-faceted, patient-centered interventions that address a diverse range of barriers to ET adherence.
BACKGROUND: For women with hormone receptor positive breast cancer, long-term endocrine therapy (ET) can greatly reduce the risk of recurrence, yet adherence is low- particularly among traditionally underserved populations. METHODS: The Carolina Breast Cancer Study oversampled Black and young women (<50 years of age). Participants answered an ET-specific medication adherence questionnaire assessing reasons for non-adherence. We used principal factor analysis to identify latent factors describing ET non-adherence. We then performed multivariable regression to determine clinical and demographic characteristics associated with each ET non-adherence factor. RESULTS: 1,231 women were included in analysis, 59% reported at least one barrier to ET adherence. We identified three latent factors which we defined as: habit - challenges developing medication-taking behavior; tradeoffs - high perceived side effect burden and medication safety concerns; and resource barriers - challenges related to cost or accessibility. Older age (50+) was associated with less reporting of habit (Adjusted Risk Ratio (aRR) 0.54[95% CI: 0.43-0.69] and resource barriers (aRR 0.66[0.43-0.997]), but was not associated with tradeoff barriers. Medicaid-insured women were more likely than privately-insured to report tradeoff (aRR:1.53 [1.10-2.13]) or resource barriers (aRR:4.43[2.49-6.57]). Black race was associated with increased reporting of all factors (habit: aRR 1.29[1.09-1.53]; tradeoffs: 1.32[1.09-1.60], resources: 1.65[1.18-2.30]). CONCLUSION: Barriers to ET adherence were described by three distinct factors, and strongly associated with sociodemographic characteristics. Barriers to ET adherence appear inadequately addressed for younger, Black, and publicly-insured breast cancer survivors. These findings underscore the importance of developing multi-faceted, patient-centered interventions that address a diverse range of barriers to ET adherence.
Authors: J Brett; D Fenlon; M Boulton; N J Hulbert-Williams; F M Walter; P Donnelly; B Lavery; A Morgan; C Morris; E Watson Journal: Eur J Cancer Care (Engl) Date: 2016-11-30 Impact factor: 2.520
Authors: Alfred I Neugut; Milayna Subar; Elizabeth Ty Wilde; Scott Stratton; Corey H Brouse; Grace Clarke Hillyer; Victor R Grann; Dawn L Hershman Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: Dawn L Hershman; Theresa Shao; Lawrence H Kushi; Donna Buono; Wei Yann Tsai; Louis Fehrenbacher; Marilyn Kwan; Scarlett Lin Gomez; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2010-08-28 Impact factor: 4.872
Authors: Marissa Howard-McNatt; Julia Lawrence; Susan A Melin; Edward A Levine; Perry Shen; John H Stewart Journal: Am J Surg Date: 2013-02-16 Impact factor: 2.565
Authors: K Robin Yabroff; Emily C Dowling; Gery P Guy; Matthew P Banegas; Amy Davidoff; Xuesong Han; Katherine S Virgo; Timothy S McNeel; Neetu Chawla; Danielle Blanch-Hartigan; Erin E Kent; Chunyu Li; Juan L Rodriguez; Janet S de Moor; Zhiyuan Zheng; Ahmedin Jemal; Donatus U Ekwueme Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto Journal: Lancet Date: 2013-03-09 Impact factor: 79.321
Authors: Jasmine S Sukumar; Dionisia Quiroga; Mahmoud Kassem; Michael Grimm; Namrata Vilas Shinde; Leslie Appiah; Marilly Palettas; Julie Stephens; Margaret E Gatti-Mays; Ashley Pariser; Mathew Cherian; Daniel G Stover; Nicole Williams; Jeffrey Van Deusen; Robert Wesolowski; Maryam Lustberg; Bhuvaneswari Ramaswamy; Sagar Sardesai Journal: Breast Cancer Res Treat Date: 2021-09-08 Impact factor: 4.872
Authors: Marc A Emerson; Yvonne M Golightly; Allison E Aiello; Katherine E Reeder-Hayes; Xianming Tan; Ugwuji Maduekwe; Marian Johnson-Thompson; Andrew F Olshan; Melissa A Troester Journal: Cancer Date: 2020-09-21 Impact factor: 6.860
Authors: Marc A Emerson; Katherine E Reeder-Hayes; Heather J Tipaldos; Mary E Bell; Marina R Sweeney; Lisa A Carey; H Shelton Earp; Andrew F Olshan; Melissa A Troester Journal: Curr Breast Cancer Rep Date: 2020-05-14
Authors: Whitney E Zahnd; Cathryn Murphy; Marie Knoll; Gabriel A Benavidez; Kelsey R Day; Radhika Ranganathan; Parthenia Luke; Anja Zgodic; Kewei Shi; Melinda A Merrell; Elizabeth L Crouch; Heather M Brandt; Jan M Eberth Journal: Int J Environ Res Public Health Date: 2021-02-03 Impact factor: 3.390
Authors: Jamie M Jacobs; Emily A Walsh; Chelsea S Rapoport; Michael H Antoni; Elyse R Park; Kathryn Post; Amy Comander; Jeffrey Peppercorn; Steven A Safren; Jennifer S Temel; Joseph A Greer Journal: J Clin Psychol Med Settings Date: 2020-11-21